

5 February 2026

**Futura Medical plc**

**("Futura", "the Group" or the "Company")**

**Patent notice of allowance granted for MED3000 (Eroxon) in the US**

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that it has been granted notice of allowance of its US continuation patent (application number 19/252084) which will provide additional protection for Eroxon® (including formulation derivatives such as the Eroxon® Intense formulation) and women's product WSD4000 (currently in development) until 2040 in the US.

The new patent contains formulation claims that means the Company is confident that the granting of the patent (which is now expected before the end of Q2 2026) will trigger a US patent milestone payment of US 2.5 million under the terms of the Company's existing license agreement with Haleon.

This allowance adds to the Company's existing patent protection in Europe, Hong Kong, Taiwan and China, further consolidating its global IP. Other applications in additional markets remain pending.

**Alex Duggan, CEO of Futura, commented:** *"The grant of this patent in the US will be a major milestone for Futura and is one of our key objectives for 2026. The receipt of the milestone payment will secure our cash runway to support current development opportunities. The United States is the largest global market for erectile dysfunction so importantly, this patent grant will provide an enhanced competitive position for both current and potential new formulations of Eroxon; in addition it will provide protection in the US for our development product WSD4000."*

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014 as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019.

**Contacts:**

<b>Futura Medical plc</b>	Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO	<a href="mailto:investor.relations@futuramedical.com">investor.relations@futuramedical.com</a> +44 (0)1483 685 670 <a href="http://www.futuramedical.com">www.futuramedical.com</a>
<b>Panmure Liberum</b> Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance)	+44 (0)20 3100 2000
<b>Turner Pope</b> <b>Investments (TPI)</b> <b>Ltd - Broker</b>	Guy McDougall, Andrew Thacker	+44 (0) 20 3657 0050
<b>Alma Strategic</b> <b>Communications</b>	Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters	+44 (0)20 3405 0205 <a href="mailto:futura@almastrategic.com">futura@almastrategic.com</a>

**Notes to Editors:**

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in the research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.

Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of ~~Healthcare Industry Awards and has won the~~ to date

healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.

WSD4000 is a topical treatment designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCSSUFULEMSELE